Equities Analysts Issue Forecasts for APLS Q2 Earnings

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) – Analysts at William Blair boosted their Q2 2026 EPS estimates for Apellis Pharmaceuticals in a note issued to investors on Tuesday, April 1st. William Blair analyst L. Hanbury-Brown now anticipates that the company will earn $0.20 per share for the quarter, up from their prior estimate of $0.18. The consensus estimate for Apellis Pharmaceuticals’ current full-year earnings is ($1.70) per share. William Blair also issued estimates for Apellis Pharmaceuticals’ Q3 2026 earnings at $0.33 EPS, Q4 2026 earnings at $0.47 EPS and FY2026 earnings at $1.01 EPS.

Apellis Pharmaceuticals (NASDAQ:APLS) last posted its earnings results on Friday, February 28th. The company reported ($0.29) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.37) by $0.08. The firm had revenue of $212.50 million for the quarter, compared to analysts’ expectations of $197.92 million. Apellis Pharmaceuticals had a negative return on equity of 103.11% and a negative net margin of 34.97%. The business’s revenue was up 45.2% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.73) earnings per share.

A number of other research firms also recently issued reports on APLS. Wedbush decreased their price objective on Apellis Pharmaceuticals from $30.00 to $29.00 and set a “neutral” rating for the company in a report on Monday, March 3rd. Royal Bank of Canada reduced their price target on shares of Apellis Pharmaceuticals from $26.00 to $25.00 and set a “sector perform” rating for the company in a research report on Monday, March 3rd. Scotiabank boosted their target price on Apellis Pharmaceuticals from $30.00 to $31.00 and gave the stock a “sector perform” rating in a research report on Wednesday. HC Wainwright reaffirmed a “buy” rating and set a $57.00 price target on shares of Apellis Pharmaceuticals in a report on Monday, March 3rd. Finally, JPMorgan Chase & Co. lifted their price target on shares of Apellis Pharmaceuticals from $50.00 to $54.00 and gave the stock an “overweight” rating in a research note on Tuesday, March 4th. Eight investment analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Apellis Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average target price of $45.59.

Apellis Pharmaceuticals Stock Up 1.4 %

Shares of NASDAQ APLS opened at $23.00 on Thursday. The firm has a fifty day simple moving average of $26.58 and a two-hundred day simple moving average of $29.21. The firm has a market capitalization of $2.89 billion, a PE ratio of -11.33 and a beta of 0.92. The company has a current ratio of 4.36, a quick ratio of 3.73 and a debt-to-equity ratio of 1.91. Apellis Pharmaceuticals has a 12 month low of $21.70 and a 12 month high of $58.12.

Hedge Funds Weigh In On Apellis Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. EverSource Wealth Advisors LLC raised its holdings in shares of Apellis Pharmaceuticals by 2,707.1% during the 4th quarter. EverSource Wealth Advisors LLC now owns 786 shares of the company’s stock worth $25,000 after acquiring an additional 758 shares in the last quarter. Signaturefd LLC raised its stake in Apellis Pharmaceuticals by 357.2% during the fourth quarter. Signaturefd LLC now owns 1,175 shares of the company’s stock valued at $37,000 after purchasing an additional 918 shares in the last quarter. GF Fund Management CO. LTD. bought a new position in Apellis Pharmaceuticals during the fourth quarter valued at $83,000. US Bancorp DE grew its stake in shares of Apellis Pharmaceuticals by 70.0% in the 4th quarter. US Bancorp DE now owns 3,223 shares of the company’s stock worth $103,000 after buying an additional 1,327 shares in the last quarter. Finally, Covestor Ltd increased its holdings in shares of Apellis Pharmaceuticals by 1,819.2% in the 4th quarter. Covestor Ltd now owns 3,992 shares of the company’s stock worth $127,000 after buying an additional 3,784 shares during the last quarter. 96.29% of the stock is owned by institutional investors.

Insider Buying and Selling

In other Apellis Pharmaceuticals news, insider Caroline Baumal sold 2,816 shares of the business’s stock in a transaction on Monday, January 6th. The shares were sold at an average price of $33.81, for a total value of $95,208.96. Following the sale, the insider now owns 55,560 shares in the company, valued at $1,878,483.60. The trade was a 4.82 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, General Counsel David O. Watson sold 5,569 shares of the firm’s stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $25.10, for a total value of $139,781.90. Following the transaction, the general counsel now owns 138,730 shares of the company’s stock, valued at approximately $3,482,123. The trade was a 3.86 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 66,054 shares of company stock valued at $1,952,719. Corporate insiders own 6.80% of the company’s stock.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).